USA & Canada

Aspen Pharmacare Canada was founded in 2014 to support our products distributed in this region. The development of our complex API capabilities into niche FDF offerings represents an opportunity for future product launches in the United States. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.

Key Countries

Canada
USA

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Canadian pharmaceutical sector is estimated to grow 4,9% to USD28,4 billion in 2018.
The US pharmaceutical sector continues to be the world’s largest and growth is expected to average 6% to 9% through to 2021.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2016: 1)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USD97 million

3 – 5 years

USD1 671 million

Number of product recalls:

Nil

(2016: nil)

Average staff turnover:

24,1%

(2016: 15,9%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

Revenue – R’billion	2017	2016 (CER)*	% change
Total	1,1	0,6	69
Anaesthetics	0,3	–	>100
Thrombosis	–	0,1	(83)
High Potency & Cytotoxics	0,3	0,4	(20)
Other Commercial Pharmaceutical Brands	0,5	0,1	>100

* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.